聚乙二醇修饰重组人白细胞介素-2及其生物学特性  被引量:2

CHEMICAL MODIFICATION OF RECOMBINANT HUMAN INTERLEUKIN2 AND ITS BIOLOGICAL CHARACTERIZATION

在线阅读下载全文

作  者:王立夫[1] 吴裕忻[1] 乔敏敏[1] 

机构地区:[1]上海第二医科大学附属瑞金医院内科消化研究室

出  处:《中国免疫学杂志》1998年第2期94-98,共5页Chinese Journal of Immunology

摘  要:采用聚乙二醇活性酯(PEG-5000)化学修饰重组人白细胞介素-2(rIL-2)及修饰后复性制得修饰产物PEG-rIL-2。PEG-rIL-2系列研究:经SDS-PAGE和CTLL-2短期细胞培养结合3H-TdR掺入法测定,PEG-rIL-2分子量为25kD,生物活性保留69.7%;采用LDH释放法测定证实PEG-rIL-2激活的LAK细胞对人体肝癌细胞BEL-7402和K562细胞的杀伤作用和rIL-2相近甚至强于rIL-2;小鼠体内的药代动力学研究表明,经静脉给药后,PEG-rIL-2较rIL-2的系统清除率降低了7.7倍,清除相半衰期延长了12倍。提示PEG修饰rIL-2后可能改变目前肿瘤免疫法中rIL-2的剂量方案,减少其用量和不良反应。The recombinant human interleukin2(rIL2) was chemically modified by an active ester of polyethylene glycol (PEG5000), and the properties of modified rIL2 (PEGrIL2) were investigated after purifcation and renaturation. The effective molecular size of PEGrIL2 characterized by SDSPAGE was 25 kD. The bioactives of rIL2 and PEGrIL2 were determined by using the standard short term proliferation response measured by 3 H thymidine incorporation into CTLL2 cells.The bioactivity of PEGrIL2 decreased slightly. Activation of LAK cells by PEGrIL2 and rIL2 were compared. The cytotoxic activity of LAK cells to K562 cells and BEL7402 cells were determined by using the coloremetric LDH assay, and PEGrIL2 gave results similar to those with rIL2 alone. The pharmacokinetics of rIL2 and PEGrIL2 after intravenous injection in mice were studied. Unmodified rIL2 is cleared from plasma with half lives of 2 min and 11 min for the α and β phases. The α and β halflives of PEGrIL2 were 8 min and 142 min, respectively. Modification of rIL2 with PEG increased the β halflives as much as 12fold.For PEGrIL2 the systemic clearance rate was decreased 7.7fold from 0.165 to 0.019 ml/min. These results suggest that chemical modification of rIL2 by PEG would have a increasing antitumor potency of in lowdose administration into human, and would also markly reduce the toxic sideeffects.

关 键 词:白细胞介素2 化学修饰 聚乙二醇 生物学特性 

分 类 号:R979.5[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象